Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
Garay R, Citrome L, Samalin L, Liu C, Thomsen M, Correll C, Hameg A, Llorca P. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opinion On Pharmacotherapy 2016, 17: 921-936. PMID: 26831200, DOI: 10.1517/14656566.2016.1149164.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsClinical Trials, Phase III as TopicCognition DisordersEuropean UnionHumansPsychotic DisordersRegistriesSchizophreniaSchizophrenic PsychologyUnited StatesConceptsCognitive impairment associated with schizophreniaSchizoaffective disorderNegative symptomsDopamine D2 receptor partial agonistTreatment of cognitive impairment associated with schizophreniaD2 receptor partial agonistTreating positive symptomsReceptor partial agonistEU clinical trial registriesAdd-on compoundsTardive dyskinesiaPositive symptomsGoal of recoverySchizophreniaPartial agonistAntipsychoticsSchizoaffectivePhase III of clinical developmentTherapeutic improvementDisordersClinical Trials RegistrySymptomsPharmacodynamic profileClinical developmentAcademic medical center